| |MAY 202519care within a field dominated by technology and scientific research. The company's focus on hematopoietic stem cell transplant procedures permits it to deliver customized medical solutions for people with blood cancer treatment needs. The Bioactive Regenerative Tooth Implant (BARTI), developed by the company, offers periodontists an innovative tool for conducting more effective clinical research using preserved pulp cells. Through its partnerships and working relationships with leading research institutions and hospitals, the firm stays updated with scientific discoveries, which enables it to continue offering breakthrough, transformative solutions. Regulatory and Ethical ComplianceTranscell Biosciences operates within a mature regulatory framework for bio-banking and personalized medicine, ensuring compliance with licensing protocols and standard operating procedures. The company's expertise and long-standing experience allow it to meet existing standards and contribute to strengthening the ecosystem that supports excellence in patient care and compliance with legal guidelines regarding the use of biological samples and patient information. The team focuses on innovation while adhering to regulations and building trust with regulators and stakeholders. This approach ensures them to innovate responsibly, protect patient rights, and improve transparency and credibility.Strategic Partnerships & Global Reach The company plans to establish partnerships with various cancer care centres across India, with the intention of expanding into Asia, the UAE, and Africa. The goal is to personalize stem cell transplantation and management for families with a history of cancer, offering services that include genetic predisposition profiling before the implementation of specialized treatments. Furthermore, there is an objective to collaborate with pharmaceutical companies in India to develop innovative and affordable cancer treatments. The company also aims to partner with periodontists in India to provide pulp cells from a biobank and support the use of cell technology for personalized treatments of periodontal diseases. Additionally, they seek to collaborate with plasma fractionation companies in India by supplying new additives intended to enhance their output and reduce reliance on imports. Future Vision and LeadershipThe vision of the company is to establish itself as a highly valued bio-bank that plays a crucial role in delivering innovative treatments and cure options for chronic diseases. They are committed to harnessing cutting-edge cell technology and foundational expertise to create transformative medical solutions that address the urgent healthcare needs of patients in India. By focusing on the development of personalized medicine and leveraging population-level clinical informatics, the passionate team aims to unlock new pathways for affordable treatments, thereby improving patient outcomes and enhancing the quality of life for those who require medical attention. With Uday Chatterjee of Indian Angel Network mentoring the team, they harmoniously align with the values of their investors and stakeholders, including clients, fostering a future full of potential. POOur state-of-the-art laboratories and unwavering commitment to strict global standards enable us to translate research breakthroughs into practical clinical applications, ensuring that patients benefit from personalized, effective treatments
< Page 9 | Page 11 >